New evidence backs AMH to personalize fertility treatment

4 July 2018

An analysis of Phase III data further supports existing evidence showing that anti-Müllerian hormone (AMH) is a reliable predictor of ovarian response to fertility treatment.

Privately-held Swiss firm Ferring Pharmaceuticals announced the new analysis of data from the ESTHER-1 trial showing that natural variations in AMH levels during and between a woman’s menstrual cycle have no clinically relevant impact on ovarian response when using AMH to dose its human recombinant follicle stimulating hormone Rekovelle (follitropin delta) for ovarian stimulation (OS).

The data were presented at the 34th Annual Meeting of the European Society of Human Reproduction and Embryology in Spain earlier this week.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK